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ABSTRACT                        The aim of this study was to determine the incidence of human papillomavirus 
(HPV) in cervical carcinoma patients. A nested case-control study was performed to investigate 
the relationship between HPV infection and cervical carcinoma. A total of 347 women 169 of 
whom gave abnormal Pap smear tests; were recruited to participate in the study; 39 of them 
suffered from invasive carcinoma. The overall incidence of HPV infection in the cancer, positive 
cytology and normal cytology groups was 74% (29/39), 55% (72/130) and 4% (7/178), respectively 
(p<0.001). The risk for progression to cervical carcinoma when the HPV infection was associated 
with abnormal cytology was 2.16 (95%, CI: [1.01-4.69]). The incidence of HPV infection associated 
with abnormal cytology correlated significantly with the presence of cervical carcinoma.
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Infection of the uterine cervix with human papillomavirus 
(HPV) usually occurs via sexual transmission; it can lead 
to malignant transformation. It is now believed that at least 
17 types of HPV are associated with cervical cancer. The 
oncogenic virus type can be identified in nearly all the cervi-
cal cancers. They are not only associated with, but are also 
thought to be causative, of the cancer. Various mechanisms 
that contribute to the development of HPV-induced cancer 
have been described. The multistep process from HPV infec-
tion to carcinogenesis is not yet completely understood. HPV 
genetic sequences have been observed to be integrated into 
the host genome just as the cell develops invasive properties 
(Cullen et al. 1991). The E6 protein produced by high-risk 
HPV types 16 and 18 is known to be able to combine with 
the p53 protein and to cause the same functional consequence 
as a p53 gene mutation (Scheffner et al. 1990; Hoppe-Seyler 
and Butz 1993). Immunosuppression can also give rise to an 
increased risk of cervical neoplasia. Immunosuppression has 
been found to be associated with an increased rate of HPV 
infection in several studies (Sillman et al. 1984; Vermund et 
al. 1991) and, in consequence of the deficient host-regula-
tory mechanisms, allows neoplastic proliferation (Rock et al. 
2000). HPV types 16, 18, 33, 31, 53 and 58 are most com-
monly associated with cervical oncogenesis. However, there 
is considerable heterogeneity in the geographic distribution 
of oncogenic HPV.
Previous studies have investigated the prevalence and 
risk factors of HPV infection in Hungary, but not in associa-
tion with cervical carcinoma (Deák et al. 1999; Nyári et al. 
2004).
The aim of this study was to determine the incidence of 
HPV in cervical carcinoma patients, in order to facilitate the 
prediction of the possibility of development of cervical cancer 
in certain groups (high-risk HPV-infected patients).
Materials and Methods
During the period between January 2002 and September 
2003, a nested case-control study was performed to inves-
tigate the relationship between HPV infection and cervical 
carcinoma at the Department of Obstetrics and Gynaecology 
of the University of Szeged. Cervical samples were collected 
for cytology and HPV testing from women attending the 
gynaecological outpatient clinic. Colposcopic and routine 
gynaecological examinations were performed in each case. 
Both the Papanicolau (Pap) and Bethesda classifications were 
used for cytology evaluation. Sampling, sample transport 
and HPV DNA determination via HPV hybrid capture assay 
were carried out in accordance with the instructions of the 
manufacturer of the kit (DIGENE HPV hybrid capture 2). 
Virus types were classified into two categories: high-risk HPV 
(including 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 
68), and low-risk (6, 11, 42, 43 and 44) types. 
Data concerning age, occupation, lifestyle and health 
status were extracted from the patient register system. 
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Statistical analyses were carried out with the STATA 
software package. The statistical methods used were the 
chi-square test and analysis of variance. To obtain an over-
view of the risk, logistic regression analysis was performed. 
A probability level of p < 0.05 was considered statistically 
significant.
Results
A total of 347 women with a mean of age of 42.9 years (SD 
9.5) were recruited into the case-control study: 178 of them 
gave normal Pap smear test (these women served as control 
group) and 169 women gave abnormal Pap smear test (class 
III or higher), 39 of them were diagnosed with invasive car-
cinoma. This later group immediately underwent appropriate 
treatment. 
The overall incidence of HPV infection in the cancer, pos-
itive cytology and normal cytology groups was 74% (29/39), 
55% (72/130) and 4% (7/178), respectively (p<0.001). 
High-risk HPV subtypes were diagnosed in 86% (25/29 
cases) of the HPV-infected cancer cases, 16% (12/72) of the 
HPV-infected cases of those who gave abnormal Pap smear 
test. The distribution of the HPV subtypes is shown in Table 
1 and the age-specific distribution of HPV infection in Table 
2. There were 46 and 5 low-grade squamous intraepithelial 
lesions cases in the abnormal Pap smear group and the control 
group, respectively. 
HPV infection significantly increased the risk of ab-
normal cytology (odds ratio (OR) 30.5 95% confidence 
interval (CI) [13.3-70]) and the risk of cervical carci-
noma (OR 68.8 95%, CI [24.2-195.6]). Further, the OR 
for progression to cervical carcinoma when the HPV in-
fection was associated with abnormal cytology was 2.16 
(95%, CI: [1.01-4.69]).
We did not find any significant difference in the incidence 
of HPV as a function of the place of residence or the previous 
obstetrical history of the women.
Discussion
The present study focused on the relationship between the 
incidence of HPV infection and that of cervical cancer. HPV 
infection associated with abnormal cytology correlated sig-
nificantly with the development of cervical carcinoma.
In the 39 cancer cases, we found a rate of HPV infection 
of 74% (29 cases), 25 of these patients were infected by 
high-risk HPV, i.e. the proportion of high-risk HPV among 
the HPV-infected cancer patients was very high (86%). The 
corresponding proportion among the HPV-infected non-
cancer patients was only 16% (12/72). The odds ratio for the 
progression to cervical carcinoma when the HPV infection 
was associated with abnormal cytology was 2.16 which 
represents significantly increased risk to develop cervical 
carcinoma (Branca et al. 2003). 
In the second half of the 1990s, HPV testing was generally 
  Control group    Abnormal Pap smear group   
 
Age Number of  Number of Total % of Number of Number of Total % of 
 HPV-negative  HPV-infected   infected HPV-negative HPV-infected  infected 
 cases cases  cases csaes csaes  cases 
        
20-29 years 0 0 0  10 30 40 75% 
30-39 years 41 1 42 2% 10 21 31 68% 
40-49 years 94 6 100 6% 25 15 40 38% 
50-59 years 36 0 36 0% 9 6 15 40% 
60-69 years 0 0 0  4 0 4 0% 
Total 171 7 178 4% 58 72 130 55% 
  Cervix carcinoma group
 
Age Number of Number of Total % of
 HPV-negative HPV-infected  infected
 cases cases  cases
       
20-29 years 0 0 0 
30-39 years 2 4 6 67%
40-49 years 3 12 15 80%
50-59 years 4 5 9 56%
60-69 years 1 8 9 89%
Total 10 29 39 74%
Table 2. Age-specific distribution of HPV infection (n=347).
Table 1. Distribution of HPV infections according to subtypes.
Group   No. of cases  p value
  Negative Low-risk High-risk Total 
   types types
Normal Pap smear  171 4 3 178 <0.001
Abnormal Pap smear  58 60 12 130
  without 
  cervical carcinoma  
Cervical carcinoma 10 4 25 39
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applied for the clinical screening of women of fertile age in 
Hungary. However, with regard to the results of international 
studies on large numbers of patients, and from cost-benefit 
considerations this practice was later modified (Schafer et al. 
1991). We currently perform HPV testing only when this is 
suggested by the results of cytological examinations carried 
out because of the possibility of HPV infection.
The regular clinical screening of HPV-infected patients 
and their treatment by conization has effectively reduced the 
development of cervical cancer (Rock et al. 2000; Tachezy 
et al. 2003). One result of our study was a knowledge of the 
incidence of HPV infection in cervical cancer in Hungary, 
which had previously not been well documented.
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